



(19) Europäisches Patentamt  
 European Patent Office  
 Office européen des brevets



(11) Publication number:

**0 535 346 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 02.11.95 (51) Int. Cl. 6: **C07C 237/26, A61K 31/65**

(21) Application number: **92114054.7**

(22) Date of filing: **18.08.92**

The file contains technical information submitted  
 after the application was filed and not included in  
 this specification

(61) **9-amino-7-substituted-6-demethyl-6-deoxytetracyclines.**

(30) Priority: **04.10.91 US 771697**

(43) Date of publication of application:  
**07.04.93 Bulletin 93/14**

(45) Publication of the grant of the patent:  
**02.11.95 Bulletin 95/44**

(34) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
 PT SE**

(56) References cited:

<b>DE-A- 2 346 535</b>	<b>US-A- 3 226 436</b>
<b>US-A- 3 338 963</b>	<b>US-A- 3 341 585</b>
<b>US-A- 3 373 198</b>	<b>US-A- 3 397 230</b>

**THE PHARMACOLOGICAL BASIS OF THERAPEUTICS. LS GOODMAN ET AL., 5th Edition, MacMillan Publishing Company, New York 1975, page 1183**

(73) Proprietor: **AMERICAN CYANAMID COMPANY  
 One Cyanamid Plaza  
 Wayne, NJ 07470-8426 (US)**

(72) Inventor: **Hlavka, Joseph J.  
 Tower Hill Road  
 Tuxedo Park,  
 New York 10987 (US)**  
**Inventor: Sum, Phalk-Eng  
 16 Chamberlain Court  
 Pomona,  
 New York 10970 (US)**  
**Inventor: Gluzman, Yakov  
 24 Peachtree Place  
 Upper Saddle River,  
 New Jersey 07458 (US)**  
**Inventor: Lee, Ving J.  
 19 Shuart Road  
 Monsey,  
 New York 10952 (US)**

(74) Representative: **Wächtershäuser, Günter, Prof.  
 Dr.  
 Patentanwalt,  
 Tal 29  
 D-80331 München (DE)**

**EP 0 535 346 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**Description****1. Field of the Invention**


5 The invention relates to novel [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4-(dimethylamino)-7-(substituted amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamides, hereinafter called 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and are useful as antibacterial agents. The invention also relates to novel 7-(substituted amino)-9-nitro-6-demethyl-6-10 deoxytetracycline compounds useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.

**DESCRIPTION OF THE PRIOR ART**


15 A variety of tetracycline antibiotics have been synthesized and described for the treatment of infectious diseases in man and animals since 1947. Tetracyclines inhibit protein synthesis by binding to the 30S subunit of the bacterial ribosome preventing binding of aminoacyl RNA (Chopra, *Handbook of Experimental Pharmacology*, Vol. 78, 317-392, Springer-Verlag, 1985). Resistance to tetracyclines has emerged among many clinically important microorganisms which limit the utility of these antibiotics. There are two major 20 mechanisms of bacterial resistance to tetracyclines: a) energy-dependent efflux of the antibiotic mediated by proteins located in the cytoplasmic membrane which prevents intracellular accumulation of tetracycline (S. B. Levy, et al., *Antimicrob. Agents Chemotherapy* 33, 1373-1374 (1989); and b) ribosomal protection mediated by a cytoplasmic protein which interacts with the ribosome such that tetracycline no longer binds or inhibits protein synthesis (A. A. Salyers, B. S. Speers and N. B. Shoemaker, *Mol. Microbiol.* 4:151-156, 25 1990). The efflux mechanism of resistance is encoded by resistance determinants designated tetA-tetL. They are common in many Gram-negative bacteria (resistance genes Class A-E), such as Enterobacteriaceae, Pseudomonas, Haemophilus and Aeromonas, and in Gram-positive bacteria (resistance genes Class K and L), such as Staphylococcus, Bacillus and Streptococcus. The ribosomal protection mechanism of resistance is encoded by resistance determinants designated TetM, N and O, and is common in 30 Staphylococcus, Streptococcus, Campylobacter, Gardnerella, Haemophilus and Mycoplasma (A. A. Salyers, B. S. Speers and N. B. Shoemaker, *Mol. Microbiol.* 4:151-156 1990).

35 A particularly useful tetracycline compound is 7-(dimethylamino)-6-demethyl-6-deoxytetracycline, known as minocycline (US-A-3,148,212, RE 26,253 and US-A-3,226,436 discussed below). However, strains harboring the tetB (efflux in gram-negative bacteria) mechanism, but not tetK (efflux in Staphylococcus) are 40 resistant to minocycline. Also, strains carrying tetM (ribosomal protection) are resistant to minocycline. This invention describes the synthesis of novel tetracycline compounds which demonstrate significant in vitro and in vivo activity vs. tetracycline and minocycline susceptible strains and some tetracycline and minocycline resistant strains, that is, those harboring the tetM (ribosomal protection) resistance determinants.


45 Duggar, US-A-2,482,055, discloses the preparation of Aureomycin® (I) by fermentation which have antibacterial activity. Growich et al., US-A-3,007,965, disclose improvements to the fermentation preparation of I. Neither of these patents teaches or suggests the 6-demethyl-6-deoxytetracyclines.




55 Beereboom et al., US-A-3,043,875 discloses tetracycline derivatives of the formulae (II) and (III) where R is H or CH<sub>3</sub>; R<sub>1</sub> is H and when R is CH<sub>3</sub>, OH; R<sub>2</sub> is H and N(CH<sub>3</sub>)<sub>2</sub>; X and Y are halogen; Z is H and halogen and B is bromo, chloro and iodo, which have antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at Y or Z) and an amino function (at B).



10 Boothe et al., US-A-3,148,212, reissued as RE26,253, and Petisi et al., US-A-3,226,436, discloses tetracycline derivatives of the formula (IV) wherein R is hydrogen or methyl and R<sub>1</sub> and R<sub>2</sub> is hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R<sub>1</sub> and R<sub>2</sub> cannot both be hydrogen, which are useful for treating bacterial infections. This patent does not teach or suggest the inclusion of a 9-  
15 amino functionality (at R<sub>2</sub>).




25 Blackwood et al., US-A-3,200,149 discloses tetracycline derivatives of the formulae (V) and (VI) and reduction products thereof wherein Y may be hydrogen or hydroxyl, X may be hydrogen, chloro, iodo, or bromo, X<sub>1</sub> may be hydrogen, amino, and lower alkanoylamino, X<sub>2</sub> may be hydrogen or nitro and Z is chloro or fluoro which possess microbiological activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino group (at X) and another nitrogen functionality (at X<sub>1</sub>) on the 6-demethyl-6-deoxytetracycline nucleus.



45 Petisi et al., US-A-3,338,963 discloses tetracycline compounds of the formula (VII) wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen, nitro, amino, formylamino, acetylamino, p-(dihydroxyboryl)benzoylamino, p-(aminobenzenesulfonyl)amino, chlorine, bromine or diazonium with the proviso that R<sub>1</sub> and R<sub>2</sub> may not both be hydrogen and with the further proviso that when R<sub>1</sub> is chlorine or bromine, R<sub>2</sub> may not be hydrogen and vice versa, R<sub>3</sub> is hydrogen or methyl and R<sub>4</sub> is hydrogen or hydroxy, which have broad-spectrum antibacterial activity. This  
50 patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R<sub>1</sub>) and amino substituents (at R<sub>2</sub>).

5




VII

10

Bitha et al., U.S. Patent No. 3,341,585 discloses tetracycline compounds of the formula (VIII) wherein R<sub>5</sub> is hydrogen,  $\alpha$ -hydroxy or  $\beta$ -hydroxy, R<sub>6</sub> is  $\alpha$ -methyl or  $\beta$ -methyl, and R<sub>7</sub> and R<sub>9</sub> are each hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R<sub>7</sub> and R<sub>9</sub> cannot both be hydrogen and with the further proviso that when R<sub>5</sub> is hydrogen then R<sub>6</sub> is  $\alpha$ -methyl. A preferred embodiment of the general formula (VIII) is when R<sub>5</sub> is  $\alpha$ -hydroxy or  $\beta$ -hydroxy, R<sub>6</sub> is  $\alpha$ -methyl or  $\beta$ -methyl, R<sub>7</sub> is di(lower alkyl)amino and R<sub>9</sub> is hydrogen, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R<sub>7</sub>) and amino substituents (at R<sub>9</sub>).

20

25




VIII

30

Shu, US-A-3,360,557 discloses 9-hydroxytetracyclines of the formula (IX) wherein R<sub>1</sub> is hydrogen or hydroxy, R<sub>2</sub> is hydrogen or hydroxy, R<sub>3</sub> is hydrogen or methyl, R<sub>2</sub> and R<sub>3</sub> taken together is methylene, and R<sub>4</sub> is hydrogen, halogen, nitro, amino, mono(lower alkyl)amino or di(lower alkyl)amino, which have been found to possess antibacterial activity. This patent is restricted to 9-hydroxytetracyclines and does not teach or suggest the presently claimed compounds.

40


45




IX

Zambrano, US-A-3,360,561 discloses a process for preparing 9-nitrotetracyclines of the formula (X) wherein R<sub>5</sub> is hydrogen or hydroxy, R<sub>1</sub> is hydrogen or hydroxy, R<sub>6</sub> is hydrogen or methyl, R<sub>1</sub> and R<sub>6</sub> taken together is methylene, R<sub>7</sub> is hydrogen, chloro or nitro and R<sub>9</sub> is hydrogen or nitro with the proviso that R<sub>7</sub> and R<sub>9</sub> cannot both be hydrogen. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at R<sub>7</sub>) and an amino functionality (at R<sub>9</sub>).

55



15 Martell et al., US-A-3,518,306 discloses 7-and/or 9-(N-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines of the formula (XI) which possess *in vivo* antibacterial activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at C-7) and an amino functionality (at C-9).




30 US-A-5,021,407, a method of overcoming the resistance of tetracycline resistant bacteria is disclosed. The method involves utilizing a blocking agent compound in conjunction with a tetracycline type antibiotic. This patent does not disclose novel tetracycline compounds which themselves have activity against resistant organisms.


35 In summary, none of the above patents teach or suggest the novel compounds of this application. In addition, none of the above patents teach or suggest novel tetracycline compounds having activity against tetracycline and minocycline resistant strains as well as strains which are normally susceptible to tetracyclines.

#### SUMMARY OF THE INVENTION

40 This invention is concerned with novel 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, represented by formula I and II, which have antibacterial activity, with methods of treating infectious diseases in warm-blooded animals employing these new compounds; with methods of treating or controlling veterinary diseases; with pharmaceutical preparations containing these compounds; with novel intermediate compounds and processes for the production of these compounds. More particularly, this invention is concerned with compound of formula I which have enhanced *in vitro* and *in vivo* antibacterial activity against 45 tetracycline resistant strains as well as a high level of activity against strains which are normally susceptible to tetracyclines.



### Formula I



### Formula 11

30 In formula I and II, R = NR<sub>1</sub>R<sub>2</sub>, and when R<sub>1</sub> = hydrogen, R<sub>2</sub> = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R<sub>1</sub> = methyl or ethyl, R<sub>2</sub> = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R<sub>1</sub> = n-propyl, R<sub>2</sub> = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R<sub>1</sub> = 1-methylethyl,

35 R<sub>2</sub> = n-butyl, 1-methylpropyl or 2-methylpropyl; and when R<sub>1</sub> = n-butyl, R<sub>2</sub> = n-butyl, 1-methylpropyl or 2-methylpropyl; and when R<sub>1</sub> = 1-methylpropyl, R<sub>2</sub> = 2-methylpropyl;

40 R<sub>3</sub> is selected from hydrogen, straight or branched (C<sub>1</sub>-C<sub>3</sub>)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C<sub>6</sub>-C<sub>10</sub>)aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; (C<sub>7</sub>-C<sub>9</sub>)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C<sub>1</sub>-C<sub>3</sub>)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH<sub>2</sub>)-,COOR<sub>5</sub> when n = 1-4 and R<sub>5</sub> is selected from hydrogen; straight or branched (C<sub>1</sub>-C<sub>3</sub>)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or (C<sub>6</sub>-C<sub>10</sub>) aryl group such as phenyl,  $\alpha$ -naphthyl,  $\beta$ -naphthyl; R<sub>4</sub> is selected from hydrogen; straight or branched (C<sub>1</sub>-C<sub>3</sub>)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C<sub>6</sub>-C<sub>10</sub>)aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; (C<sub>7</sub>-C<sub>9</sub>)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C<sub>1</sub>-C<sub>3</sub>)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH<sub>2</sub>)-,COOR<sub>6</sub> when n = 1-4 and R<sub>6</sub> is selected from hydrogen; straight or branched (C<sub>1</sub>-C<sub>3</sub>)alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or (C<sub>6</sub>-C<sub>10</sub>)aryl such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; or R<sub>3</sub> and R<sub>4</sub> taken together are -(CH<sub>2</sub>)<sub>2</sub>W(CH<sub>2</sub>)<sub>2</sub>-, wherein W is selected from (CH<sub>2</sub>)<sub>n</sub> and n = 0-1, -NH, -N(C<sub>1</sub>-C<sub>3</sub>)alkyl, -N(C<sub>1</sub>-C<sub>4</sub>)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) proline, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal complexes.

Particularly preferred are compounds according to the above formula I and II in which  $R = NR_1R_2$ , and when  $R_1 =$  hydrogen,  
 $R_2 =$  ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when  $R_1$  = methyl,  
 $R_2$  = methyl, ethyl, n-propyl, n-butyl, 1-methylpropyl or 2-methylpropyl;  
 and when  $R_1$  = ethyl,  
 $R_2$  = ethyl, n-propyl, n-butyl or 2-methylpropyl;

5 and when  $R_1$  = n-propyl,  
 $R_2$  = n-propyl, n-butyl or 2-methylpropyl;  
 and when  $R_1$  = n-butyl,  
 $R_2$  = n-butyl or 2-methylpropyl;

10  $R_3$  is selected from hydrogen, straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_5$  when  $n$  = 1-4 and  $R_5$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ ) aryl group such as phenyl,  $\alpha$ -naphthyl,  $\beta$ -naphthyl;


15  $R_4$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_6$  when  $n$  = 1-4 and  $R_6$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl such as methyl, 20 ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ )aryl such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n$  = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N-( $C_1$ - $C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) proline, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal complexes.

25 Most particularly preferred are compounds according to the above formula I and II in which  
 $R$  =  $NR_1R_2$ ,  
 and when  $R_1$  = hydrogen,  
 $R_2$  = ethyl, n-propyl or 1-methylethyl;  
 and when  $R_1$  = methyl,  


30  $R_2$  = methyl, ethyl or n-propyl; and  
 when  $R_1$  = ethyl,  
 $R_2$  = ethyl;  
 $R_3$  is selected from hydrogen, straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_5$  when  $n$  = 1-4 and  $R_5$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ ) aryl group such as phenyl,  $\alpha$ -naphthyl,  $\beta$ -naphthyl;

35  $R_4$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_6$  when  $n$  = 1-4 and  $R_6$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ )aryl such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n$  = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N-( $C_1$ - $C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) proline, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal complexes.

40 Also included in the present invention are compounds useful as intermediates for producing the above  
 50 compounds of formula I. Such intermediate compounds include those having the formulae:



Formula III



Formula IV

25

wherein:

 $R = NR_1R_2$ ,and when  $R_1$  = hydrogen,

30  $R_2$  = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;  
and when  $R_1$  = methyl or ethyl,  
 $R_2$  = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;  
and when  $R_1$  = n-propyl,  
 $R_2$  = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;  
35 and when  $R_1$  = 1-methylethyl,  
 $R_2$  = n-butyl, 1-methylpropyl or 2-methylpropyl;  
and when  $R_1$  = n-butyl,  
 $R_2$  = n-butyl, 1-methylpropyl or 2-methylpropyl;  
and when  $R_1$  = 1-methylpropyl,  
40  $R_2$  = 2-methylpropyl;  
 $R_3$  is selected from hydrogen, straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -( $CH_2$ )-  
45  $_nCOOR_5$  when  $n = 1$ -4 and  $R_5$  is selected from hydrogen, straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl,  $\beta$ -naphthyl;  
 $R_4$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -( $CH_2$ )-  
50  $_nCOOR_5$  when  $n = 1$ -4 and  $R_5$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ ) aryl such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; or  $R_3$  and  $R_4$  taken together are -( $CH_2$ ) $_2W(CH_2)$  $_2-$ , wherein  $W$  is selected from ( $CH_2$ ) $_n$  and  $n = 0$ -1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N-( $C_1$ - $C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D)  
55 proline, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal complexes.

Particularly preferred are compounds according to the above formula III and IV in which  $R = NR_1R_2$ , and when  $R_1$  = hydrogen,

$R_2$  = ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;  
and when  $R_1$  = methyl,  
 $R_2$  = methyl, ethyl, n-propyl, n-butyl, 1-methylpropyl or 2-methylpropyl;  
and when  $R_1$  = ethyl,

5  $R_2$  = ethyl, n-propyl, n-butyl or 2-methylpropyl;  
and when  $R_1$  = n-propyl,  
 $R_2$  = n-propyl, n-butyl or 2-methylpropyl;  
and when  $R_1$  = n-butyl,  
 $R_2$  = n-butyl or 2-methylpropyl;

10  $R_3$  is selected from hydrogen, straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -( $CH_2$ )<sub>n</sub>COOR<sub>5</sub> when n = 1-4 and R<sub>5</sub> is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as 15 methyl, ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ ) aryl group such as phenyl,  $\alpha$ -naphthyl,  $\beta$ -naphthyl;  
 $R_4$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -( $CH_2$ )<sub>n</sub>COOR<sub>6</sub> when n = 1-4 and R<sub>6</sub> is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl such as methyl, 20 ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ )aryl such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; or R<sub>3</sub> and R<sub>4</sub> taken together are -( $CH_2$ )<sub>2</sub>W( $CH_2$ )<sub>2</sub>-, wherein W is selected from ( $CH_2$ )<sub>n</sub> and n = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N-( $C_1$ - $C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) proline, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic 25 salts, and metal complexes.


Most particularly preferred are compounds according to the above formula III and IV in which R = NR<sub>1</sub>R<sub>2</sub>, and when R<sub>1</sub> = hydrogen,  
 $R_2$  = ethyl, n-propyl or 1-methylethyl;  
and when  $R_1$  = methyl,

30  $R_2$  = methyl, ethyl or n-propyl;  
and when R<sub>1</sub> = ethyl,  
 $R_2$  = ethyl;  
 $R_3$  is selected from hydrogen, straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as 35 benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -( $CH_2$ )<sub>n</sub>COOR<sub>5</sub> when n = 1-4 and R<sub>5</sub> is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ ) aryl group such as phenyl,  $\alpha$ -naphthyl,  $\beta$ -naphthyl;  
 $R_4$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; ( $C_6$ - $C_{10}$ )aryl group such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; ( $C_7$ - $C_9$ )aralkyl group such as 40 benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -( $CH_2$ )<sub>n</sub>COOR<sub>6</sub> when n = 1-4 and R<sub>6</sub> is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or ( $C_6$ - $C_{10}$ )aryl such as phenyl,  $\alpha$ -naphthyl or  $\beta$ -naphthyl; or R<sub>3</sub> and R<sub>4</sub> 45 taken together are -( $CH_2$ )<sub>2</sub>W( $CH_2$ )<sub>2</sub>-, wherein W is selected from ( $CH_2$ )<sub>n</sub> and n = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N( $C_1$ - $C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) proline, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal complexes.

50 **DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The novel compounds of the present invention may be readily prepared in accordance with the following schemes.

The starting 7-(substituted amino)-6-demethyl-6-deoxytetracyclines described in formula 1, wherein 55 R = NR<sub>1</sub>R<sub>2</sub> and R<sub>1</sub> = R<sub>2</sub> (1a) and R = NHR<sub>2</sub> (1b) or the salts thereof are prepared by procedures known to those skilled in the art including those described in U.S. Patents 3,226,436 and 3,518,306.



5

10

$$1a = R = NR_1 R_2, R_1 = R_2$$


$\bar{1}b = R = NHR_2$

$$\bar{1}_C = R = NR_1R_2, R_1 \neq R_2$$

The starting 7-(substituted amino)-6-demethyl-6-deoxytetracyclines described in formula 1 wherein R = NR<sub>1</sub> R<sub>2</sub> and R<sub>1</sub> ≠ R<sub>2</sub> (1c) are prepared according to Scheme 1.

**Scheme 1**

20



35

In accordance with Scheme I, a 7-(monoalkylamino)-6-demethyl-6-deoxytetracycline, **1b**, in which  $R = NHR_2$ , is reductively alkylated with an aldehyde to give an unsymmetrical dialkylamino, **1c**.


40

45

50

55

### Scheme 11



25 In accordance with Scheme II, a 7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 1a-1c, is treated with

30 a) a metal nitrate salt; such as calcium, potassium or sodium; and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid or  
b) nitric acid and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid; to form the corresponding 7-(substituted amino)-9-nitro-6-demethyl-6-deoxytetracycline 2.


35 To produce the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines of the present invention, compound 2 or its salts is treated with hydrogen in an acid alcohol solvent, preferably 2-methoxyethanol, in the presence of a suitable catalyst such as, for example:

40 a) any supported catalyst; such as 0.5-25% palladium-on-carbon, 0.5-25% palladium-on-barium sulfate, 0.5-25% platinum-on-carbon or 0.5-25% rhodium-on-carbon; .  
b) any reducible metal oxide catalyst; such as Raney nickel or platinum oxide; or  
c) a homogeneous hydrogenation catalyst; such as tris(triphenylphosphine)rhodium (I) chloride; to obtain the 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 3.

45 Alternatively, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines of the present invention are obtained by treating with:

50 a) stannous chloride dihydrate as described by R. B. Woodward, Org. Syn., Coll. Vol. 3, 453 (1955);  
b) a soluble metal sulfide, preferably sodium sulfide, in alcoholic solvents as described by G. R. Robertson, Org. Syn., Coll. Vol. 1, 52 (1941);  
c) an active metal in mineral acid; such as iron, tin or zinc in dilute hydrochloric acid;  
d) active metal couples; such as copper-zinc, tin-mercury or aluminum amalgam in dilute acid; or  
e) transfer hydrogenation using triethylammonium formate and a supported catalyst as described by I. D. Entwistle et al., J. Chem. Soc., Perkin 1, 443 (1977).

Scheme III



5 sensitive or tetracycline resistant (tetM+) cells is combined with a mixture of low molecular weight compounds required for protein synthesis which include a mixture of 19 amino acids, methionine, <sup>35</sup>S-methionine, plasmid template DNA and either dimethylsulfoxide (DMSO) or the tetracycline to be tested dissolved and diluted in DMSO. This mixture is incubated at 37°C for 30 minutes. Following the incubation, 2.5 µl of the 10 µl reaction is removed and added to 0.5 ml of 1N sodium hydroxide. The solution is incubated an additional 15 minutes at 37°C, to destroy any m-RNA and t-RNA. The incorporation of <sup>35</sup>S-methionine is determined by precipitating the high molecular weight material in the sodium hydroxide aliquot with trichloroacetic acid (TCA), collecting the precipitated material on Whatman G/FC filters, drying the filters and counting the radioactivity retained on the filter. Percent inhibition (P.I.) of protein synthesis is 10 determined by the following equation:

$$15 \quad P.I. = 100 - \left( \frac{\text{total CPM* retained on filter in the presence of added tetracycline compound}}{\text{Total CPM* retained on filter for DMSO (control)}} \right) \times 100$$

\*CPM = counts per minute

20 In Vivo Antibacterial Evaluation (Table 3)

25 The therapeutic effects of tetracyclines are determined against acute lethal infections with various staphylococcal and E. coli strains. Female mice, strain CD-1 Charles River Laboratories, (20 ± 2 grams) are challenged by an intraperitoneal injection of sufficient bacteria (suspended in broth or hog gastric mucin) to kill non-treated controls within 24-48 hours. Antibacterial agents, contained in 0.5 ml of 0.2% aqueous agar, are administered subcutaneously or orally 30 minutes after infection. When an oral dosing schedule is used, animals are deprived of food for 5 hours before and 2 hours after infection. Five mice are treated at each 30 dose level. The 7 day survival ratios from three separate tests are pooled for calculation of median effective dose (ED<sub>50</sub>).

Legend for Tables I - III

35 A = 9-Amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride  
 B = 7-(Dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (minocycline hydrochloride)  
 C = 9-Amino-7-(diethylamino)-6-demethyl-6-deoxytetracycline sulfate  
 D = 7-(Diethylamino)-6-demethyl-6-deoxytetracycline sulfate

40

45

50

55

Table 1

*In Vitro* Antibacterial Activity of 6-Demethyl-6-deoxytetracycline Derivatives

	Organism*	MIC (μg/ml)			
		A <sup>a</sup>	B	C <sup>a</sup>	D
	<i>S. aureus</i> UBMS 88-5 ( <i>tetM</i> )	0.06	4	0.5	16
	<i>S. aureus</i> UBMS 88-4 (tetracycline-sensitive)	0.015	0.008	0.03	0.03
10	<i>S. aureus</i> UBMS 90-1 ( <i>tetM</i> )	0.25	4	2	8
	<i>S. aureus</i> UBMS 90-2 ( <i>tetM</i> )	0.06	1	0.25	8
	<i>S. aureus</i> UBMS 90-3 (tetracycline-sensitive)	0.015	0.015	0.03	0.03
	<i>S. aureus</i> UBMS 88-7 ( <i>tetK</i> )	0.12	0.03	0.06	0.12
	<i>S. aureus</i> IVES 2943 (methicillin-resistant)	0.5	1	0.25	8
	<i>S. aureus</i> IVES 1983 (methicillin-resistant)	0.5	1	0.25	8
15	<i>S. aureus</i> CI 2371 (methicillin-resistant)	0.5	4	NA	NA
	<i>S. aureus</i> CI3300 (methicillin-resistant)	0.25	8	NA	NA
	Coagulase negative staphylococci CI 664	0.003	0.015	NA	NA
	Coagulase negative staphylococci CI 535	1	8	NA	NA
20	<i>S. haemolyticus</i> AVAH 88-3	0.06	0.12	0.12	NA
	<i>E. faecalis</i> AMV 120 ( <i>tetM</i> )	4	16	NA	NA
	<i>E. faecalis</i> PAM 211 ( <i>tetV</i> )	4	16	NA	NA
	<i>E. faecalis</i> 12201 (vancomycin-resistant)	0.5	4	NA	NA
25	<i>E. faecalis</i> CI 2735	0.5	4	NA	NA
	<i>E. coli</i> UBMS 88-1 ( <i>tetB</i> )	>32	8	2	32
	<i>E. coli</i> UBMS 88-2 (tetracycline-sensitive)	0.25	0.5	0.5	2
	<i>E. coli</i> UBMS 89-1 ( <i>tetM</i> )	1	8	2	NA
30	<i>E. coli</i> UBMS 89-2 (tetracycline-sensitive)	0.5	0.5	0.5	4
	<i>E. coli</i> UBMS 90-4 ( <i>tetM</i> )	4	>32	32	>32
	<i>E. coli</i> UBMS 90-5 (tetracycline-sensitive)	0.25	0.5	1	2
	<i>M. morganii</i> NEMC 87-119	2	2	2	32
35	<i>S. marcescens</i> FPOR 87-33	4	2	4	32
	<i>P. aeruginosa</i> ATCC 27853	2	4	8	32
	<i>X. malophilia</i> FPOR 87-210	0.12	0.06	0.12	0.25
	<i>E. coli</i> ATCC25922	0.25	0.25	0.50	1
	<i>E. faecalis</i> ATCC 29212	0.06	0.25	0.12	8
	<i>S. aureus</i> ATCC 29213	0.008	≤0.004	≤0.015	<0.015

<sup>a</sup> *In vitro* assay is done in the presence of cysteine (0.05%). Antibacterial potency of B and D was not enhanced in the presence of cysteine.

\* The *tetM* resistance determinant protects ribosomes from tetracycline, the *tetK* determinant promotes efflux of the drug from the cell.

45

50

55

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Table 2. *In Vitro* Protein Translation with *E. coli* S30 Ribosomes

Reaction Plus compound	Wild Type Version						tetM Variant					
	Wild Type S30 no DTT*			Wild Type S30 with DTT*			Wild Type S30 no DTT*			Wild Type S30 with DTT*		
	Counts	% Inhibition	Counts	% Inhibition	Counts	% Inhibition	Counts	% Inhibition	Counts	% Inhibition	Counts	% Inhibition
Control DMSO	457268		872132		457268		872132		457268		872132	
1.0 mg/ml	57696	87	58885	93	52595	88	38121	96	80494	82	60891	93
1:2 Dilution	76804	83	78961	91	95015	79	92203	89	130209	72	143215	84
1:4 Dilution	53400	88	111971	87	205392	55	214831	75	297786	35	238321	73
1:8 Dilution	162405	64	149792	83	518601	41	518601	41	245494	46	380103	56
1:16 Dilution	213077	53	207484	76								
1:32 Dilution	306650	33	289304	67								
1:64 Dilution	457601	0										
Control DMSO	247938		447247		247938		447247		247938		447247	
1.0 mg/ml	281528	0	371475	17	129780	48	145068	68	158861	36	168574	62
1:2 Dilution	258633	0	331439	26	203184	18	226708	49	373168	17		
1:4 Dilution	248904	0	421533	6	231447	7	284606	36	493679	0	315989	16
1:8 Dilution	289595	0	490283	0	305633	0	349994	0	412967	0		
1:16 Dilution	287498	0	452837	0	310723	0					507461	0
1:32 Dilution	262329	0										
1:64 Dilution	249242	0										

\* Dithiothreitol (DTT) is used as an oxygen scavenger.

Table 3

Effects of Compounds A and B on Acute Lethal Infections in Mice			
Organism	Route of Antibiotic Administration*	ED <sub>50</sub> (mg/kg) <sup>†</sup>	
		A	B
<i>E. coli</i> 311 (sens)	Subcutaneous	2.8	3.1
	<i>E. coli</i> UBMS 90-4 ( <i>tetM</i> )	24	>256
	<i>S. aureus</i> UBMS 90-1 ( <i>tetM</i> )	0.30	1.7
<i>S. aureus</i> UBMS 90-2 ( <i>tetM</i> )	Oral	1.6	1.8
	Subcutaneous	0.53	1.8
<i>S. aureus</i> Smith (sens)	Oral	0.81	0.53
	Subcutaneous	0.34	0.32

\* Single Dose

† Median effective dose protecting 50% of the infected mice

20

Testing Results

As seen from the above testing, the compounds according to the present invention display good activity against a spectrum of tetracycline sensitive and resistant Gram-positive and Gram-negative bacteria, especially strains of *E. coli*, *S. aureus* and *E. faecalis* containing the *tetM* or *tetK* resistant determinants. As illustrated in Table I, 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (A) shows good *in vitro* activity against tetracycline resistant strains carrying the *tetM* resistance determinant such as *S. aureus* UBMS 88-5, *S. aureus* UBMS 90-1 and 90-2, *E. coli* UBMS 89-1 and 90-4; and is equally as effective as 7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (B) vs. susceptible strains. 7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (B) and 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (A) are assayed *in vitro* for their ability to inhibit protein synthesis, taking place on either wild type or *tetM* protected ribosomes, using a coupled transcription and translation system. Similarly, 9-amino-7-(diethylamino)-6-demethyl-6-deoxytetracycline sulfate (C) shows enhancement of antibacterial activity versus 7-(diethylamino)-6-demethyl-6-deoxytetracycline sulfate (D).

Both compounds (A & B) are found to effectively inhibit protein synthesis on wild type ribosomes, having equivalent levels of activity (Table II). 7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (B) is unable to inhibit protein synthesis occurring on *tetM* protected ribosomes. In contrast, 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (A) is effective in inhibiting protein synthesis occurring on *tetM* protected ribosomes, although higher drug levels are required to achieve similar levels of inhibition relative to wild type ribosomes.

The enhanced activity of 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline sulfate (A) against tetracycline susceptible and resistant organisms (*tetM*) is demonstrated in Table 3 for animals infected with representative bacteria. Lowered ED<sub>50</sub>'s are obtained with 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline sulfate (A) than with 7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (B) in mice with of *S. aureus* and *E. coli* which carry the *tetM* resistance determinant. Similar ED<sub>50</sub>'s are obtained with 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline sulfate (A) and 7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (B) against infections with minocycline susceptible organisms.

As can be seen from Tables 1 and 3, the new 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines may be used to prevent or control important veterinary diseases such as mastitis, diarrhea, urinary tract infections, skin infections, ear infections, wound infections and the like.

The improved efficacy of the new 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines is evidenced by the *in vitro* activity against isogenic strains into which the resistant determinants, such as *tetM*, were cloned (Table 1); the inhibition of protein synthesis by *tetM* resistant ribosomes (Table 2); and the *in vivo* activity against experimental infections caused by strains resistant to the tetracyclines, due to the presence of resistant determinants, *tetM* (Table 3).

When the compounds are employed as antibacterials, they can be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for

example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from 5 about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

An effective amount of compound from 2.0 mg/kg of body weight to 100.0 mg/kg of body weight should be administered one to four times per day via any typical route of administration including but not limited to oral, parenteral (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of 10 excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient 20 and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of 25 the compounds is preferred.

These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of 30 storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating 35 action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.

The invention will be more fully described in conjunction with the following specific examples which are not to be construed as limiting the scope of the invention.

40

Example 1

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

45

To a stirred ice bath cooled solution of 0.444 g of [4S-(4 $\alpha$ ,12 $\alpha$ )]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S Patent 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.101 g of sodium nitrate. The mixture is stirred in the cold for 45 minutes followed by the dropwise 50 addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.6 g of the desired product as a solid. MS(FAB): m/z 503(M + H) and 601(M + H<sub>2</sub>SO<sub>4</sub> + H).

55

Example 2[4S-(4 $\alpha$ ,12 $\alpha$ )]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)

5

To a stirred ice cooled solution of 0.660 g of [4S-(4 $\alpha$ ,12 $\alpha$ )]-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Patent 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.151 g of sodium nitrate. The mixture is stirred in the cold followed by dropwise addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.8 g of the desired product as a solid. MS(FAB): m/z 531(M + H) and 629(M + H<sub>2</sub>SO<sub>4</sub> + H).

Example 3[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

A mixture of 2.0 g of product from Example 1 in 20 ml of 2-methoxyethanol is stirred for 10 minutes and filtered. The filtrate is shaken, in a pressure bottle, with 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid, under 30 lbs. of hydrogen pressure, for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo to half volume. The solution is poured into 100 ml of diethyl ether, the solid collected, washed with diethyl ether and dried to give 1.6 g of the desired product as a solid. MS(FAB): m/z 473(M + H).

Example 4[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12 $\alpha$ -tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride (1:1)

A mixture of 20.0 g of product from Example 1 in 250 ml of 2-methoxyethanol is stirred for 10 minutes and filtered. The filtrate is shaken, in a pressure bottle, with 10.0 g of 10% palladium-on-carbon and 100 ml of 1N ethanolic hydrogen chloride, under 30 lbs. of hydrogen pressure, for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo to half volume. The solution is poured into 1 L of diethyl ether, the solid collected, washed with diethyl ether and dried to give 16.0 g of the desired product as an oil. The oil is suspended in 20 ml of distilled water, made acidic with 2.8 ml of 32% hydrochloric acid and decolorized with charcoal. The mixture is filtered through diatomaceous earth and made basic (pH 4.0) with concentrated ammonium hydroxide. The solid is collected at 4 °C, washed with pH 4 water and dried in vacuo to give 14.2 g of the desired product as a solid.

<sup>1</sup>H NMR (CD<sub>3</sub>SOCD<sub>3</sub>):  $\delta$  4.19(s,1H,4-H) and 7.29(s,1H,8-H).

40 MS(FAB): m/z 473(M + H).

45

Analysis for C <sub>23</sub> H <sub>28</sub> N <sub>4</sub> O <sub>7</sub> HCl 6.7% H <sub>2</sub> O				
Calc'd:	C,50.64;	H,6.10;	N,10.27;	Cl,6.50
Found:	C,50.72;	H,6.07;	N,10.27;	Cl,6.62.

Example 5[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide p-toluenesulfonate (1:1)

The title compound is prepared by the procedure of Example 4, using 20 g of product from Example 1, to give 16.0 g of the desired product as the free base. The free base is suspended in 20 ml of distilled water, made acidic with p-toluenesulfonic acid monohydrate and decolorized with charcoal. The mixture is filtered through diatomaceous earth and made basic (pH 4.0) with concentrated ammonium hydroxide. The solid is collected at 4 °C, washed with pH 4 water and dried in vacuo to give 16.0 g of the desired product.

Example 6

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)

5

The title compound is prepared by the procedure of Example 3, using 2.1 g of product from Example 2, to give 1.5 g of the desired product as a solid.  $^1\text{H}$  NMR ( $\text{CD}_3\text{SOCD}_3$ ):  $\delta$  4.25(s,1H,4-H) and 7.27(s,1H,8-H). MS(FAB): m/z 501(M + H) and 599(M +  $\text{H}_2\text{SO}_4 + \text{H}$ ).

Example 7

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride (1:1)

15

A solution of 0.460 g of [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in US-A-3,226,436, 0.5 ml of 97% formic acid and 0.75 ml of 40% aqueous formaldehyde is heated at reflux temperature for 2 hours. The reaction mixture is cooled, concentrated *in vacuo* to half volume and poured into diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to 20 give 0.3 g of the desired product as a solid.

Example 8

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydro-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

The title compound is prepared by the procedure of Example 1, using 0.46 g of product from Example 7 to give 0.5 g of the desired product as a solid.

Example 9

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethylmethylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

35

The title compound is prepared by the procedure of Example 3, using 1.0 g of product from Example 8, to give 0.8 g of the desired product as a solid.

Example 10

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

45

The title compound is prepared by the procedure of Example 1, using 0.48 g of [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Patent 3,226,436, to give 0.5 g of the desired product as a solid.

Example 11

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

The title compound is prepared by the procedure of Example 3, using 2.1 g of product from Example 10, to give 1.5 g of the desired product as a solid.

55

Example 12

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

5

The title compound is prepared by the procedure of Example 1, using 0.96 g of [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide prepared by the procedure described in US-A-3,226,436, to give 0.9 g of the desired product as a solid.

10

Example 13

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

15

The title compound is prepared by the procedure of Example 3, using 1.0 g of product from Example 12, to give 0.7 g of the desired product as a solid.

20

Substantially following the methods described in detail hereinabove in Examples 3 and 9, the compounds of this invention listed below in Examples 14-35 are prepared.

25

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(methylpropylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

30

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(butylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

35

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[1-methylpropylamino)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

40

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(2-methylpropyl)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

45

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(2-methylpropyl)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

50

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

55

[4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(butylethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

Example 21

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylpropyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

5

Example 22

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(2-methylpropyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

10

Example 23

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-(dipropylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

15

Example 24

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

20

Example 25

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-(butylpropylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

25

Example 26

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylpropyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

30

Example 27

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(2-methylpropyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

35

Example 28

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

40

Example 29

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)(1-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

45

Example 30

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

50

Example 31

[4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-(dibutylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

55

Example 32

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylpropyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

5

Example 33

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(2-methylpropyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

10

Example 34

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

15

Example 35

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylpropyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

20

Examples 36-39

Substantially following the methods described in detail hereinabove in Examples 3 and 11, the compounds of this invention listed below in Examples 36-39 are prepared.

25

Example 36

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(propylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

30

Example 37

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(butylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

35

Example 38

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

40

Example 39

[4S-(4 $\alpha$ ,12a $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1,1-dimethylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.

45

Examples 40-65

Substantially following the methods described in detail hereinabove in Examples 1 and 2, the compounds of this invention listed below in Examples 40-65 are prepared.

50

Example 40

[4S-(4 $\alpha$ ,12a $\alpha$ )]-4-(Dimethylamino)-7-(methylpropylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

55

Example 41

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(butylmethylenamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

5

Example 42

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylpropylamino)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

10

Example 43

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(2-methylpropyl)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

15

Example 44

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylpropylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

20

Example 45

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

25

Example 46

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(butylethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

30

Example 47

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylpropyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

35

Example 48

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(2-methylpropyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

40

Example 49

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(dipropylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

45

Example 50

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate

50

Example 51

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(butylpropylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

55

Example 52

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylpropyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

5

Example 53

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(2-methylpropyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

10

Example 54

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

15

Example 55

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)(1-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

20

Example 56

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

25

Example 57

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(dibutylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

30

Example 58

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylpropyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

35

Example 59

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(2-methylpropyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

40

Example 60

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

45

Example 61

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylpropyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

50

Example 62

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(propylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

55

Example 63

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(butylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

5

Example 64

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

10

Example 65

[4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1,1-dimethylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.



15

**Claims**

**Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, PT, SE**

1. A compound of the formula (I) or (II):

20



wherein:

when R<sub>1</sub> = hydrogen,

45 R<sub>2</sub> = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when R<sub>1</sub> = methyl or ethyl,

R<sub>2</sub> = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R<sub>1</sub> = n-propyl,

50 R<sub>2</sub> = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R<sub>1</sub> = 1-methylethyl,

R<sub>2</sub> = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R<sub>1</sub> = n-butyl,

R<sub>2</sub> = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R<sub>1</sub> = 1-methylpropyl,

R<sub>2</sub> = 2-methylpropyl;

R<sub>3</sub> is selected from hydrogen, straight or branched (C<sub>1</sub>-C<sub>3</sub>)alkyl group; (C<sub>6</sub>-C<sub>10</sub>)aryl group; (C<sub>7</sub>-C<sub>9</sub>)-aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C<sub>1</sub>-



$C_3$ alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_5$  when  $n=1-4$  and  $R_5$  is selected from hydrogen; straight or branched  $(C_1-C_3)$ alkyl group; or  $(C_6-C_{10})$ aryl group;  
 $R_4$  is selected from hydrogen; straight or branched  $(C_1-C_3)$ alkyl group;  $(C_6-C_{10})$ aryl group;  $(C_7-C_9)$ aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1-C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_6$  when  $n=1-4$  and  $R_6$  is selected from hydrogen; straight or branched  $(C_1-C_3)$ alkyl; or  $(C_6-C_{10})$ aryl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n=0-1$ , -NH, -N( $C_1-C_3$ )alkyl, -N( $C_1-C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes.

2. The compound according to Claim 1, wherein:
 

when  $R_1$  = hydrogen,  
 $R_2$  = ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and  
   when  $R_1$  = methyl,  
 $R_2$  = methyl, ethyl, n-propyl, n-butyl, 1-methylpropyl or 2-methylpropyl;  
   and when  $R_1$  = ethyl,  
 $R_2$  = ethyl, n-propyl, n-butyl, or 2-methylpropyl;  
   and when  $R_1$  = n-propyl,  
 $R_2$  = n-propyl, n-butyl or 2-methylpropyl;  
   and when  $R_1$  = n-butyl,  
 $R_2$  = n-butyl or 2-methylpropyl;  
 $R_3$  is selected from straight or branched  $(C_1-C_3)$ alkyl group;  $(C_6-C_{10})$ aryl group;  $(C_7-C_9)$ aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1-C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_5$  when  $n=1-4$  and  $R_5$  is selected from hydrogen; straight or branched  $(C_1-C_3)$ alkyl group; or  $(C_6-C_{10})$ aryl group;  
 $R_4$  is selected from straight or branched  $(C_1-C_3)$ alkyl group;  $(C_6-C_{10})$ aryl group;  $(C_7-C_9)$ aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1-C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_6$  when  $n=1-4$  and  $R_6$  is selected from hydrogen; straight or branched  $(C_1-C_3)$ alkyl; or  $(C_6-C_{10})$ aryl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n=0-1$ , -NH, -N( $C_1-C_3$ )alkyl, -N( $C_1-C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes.
3. The compound according to Claim 1, wherein:
 

when  $R_1$  = hydrogen,  
 $R_2$  = ethyl, n-propyl or 1-methylethyl;  
   and when  $R_1$  = methyl,  
 $R_2$  = methyl, ethyl or n-propyl;  
   and when  $R_1$  = ethyl;  
 $R_2$  = ethyl;  
 $R_3$  is selected from a straight or branched  $(C_1-C_3)$ alkyl group;  $(C_6-C_{10})$ aryl group;  $(C_7-C_9)$ aralkyl group; or  $-(CH_2)_nCOOR_5$  when  $n=1-4$  and  $R_5$  is selected from hydrogen; straight or branched  $(C_1-C_3)$ alkyl group; or  $(C_6-C_{10})$ aryl group;  
 $R_4$  is selected from straight or branched  $(C_1-C_3)$ alkyl group;  $(C_6-C_{10})$ aryl group;  $(C_7-C_9)$ aralkyl group; or  $-(CH_2)_nCOOR_6$  when  $n=1-4$   
 $R_5$  is selected from hydrogen; straight or branched  $(C_1-C_3)$ alkyl; or  $(C_6-C_{10})$ aryl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n=0-1$ , -NH, -N( $C_1-C_3$ )alkyl, -N( $C_1-C_4$ )alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes.

4. A compound of the formula (I) or (II):



wherein:

when  $R_1 = \text{hydrogen}$ .

<sup>30</sup> R<sub>2</sub>=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl:

and when  $R_1 =$  methyl or ethyl.

R<sub>2</sub> = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when  $R_1 \equiv n\text{-propyl}$

$R_2 \equiv$  n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when  $R_1 = 1\text{-methylethyl}$ .

$R_3 = n\text{-butyl, 1-methylpropyl or 2-methylpropyl}$

and when  $R_1 = n\text{-butyl}$ .

$R_2 \equiv$  n-butyl, 1-methylpropyl or

and when  $R_1 = 1$ -met

**R<sub>2</sub>** = 2-methylpropyl;  
**R<sub>3</sub>** is selected from hydrogen, straight or branched (C<sub>1</sub>--C<sub>3</sub>)alkyl group; (C<sub>6</sub>--C<sub>10</sub>)aryl group; (C<sub>7</sub>--C<sub>9</sub>)-aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C<sub>1</sub>--C<sub>3</sub>)-

45  $C_3$ alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_5$  when  $n=1-4$  and  
 R<sub>5</sub> is selected from hydrogen; straight or branched ( $C_1-C_3$ )alkyl group; or ( $C_6-C_{10}$ )aryl group;  
 R<sub>4</sub> is selected from hydrogen; straight or branched ( $C_1-C_3$ )alkyl group; ( $C_6-C_{10}$ )aryl group; ( $C_7-C_9$ )-

50 aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C<sub>1</sub>-C<sub>3</sub>)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH<sub>2</sub>)<sub>n</sub>COOR<sub>6</sub> when n=1-4 and R<sub>6</sub> is selected from hydrogen; straight or branched (C<sub>1</sub>-C<sub>3</sub>)alkyl; or (C<sub>6</sub>-C<sub>10</sub>)aryl; or R<sub>3</sub> and R<sub>4</sub> taken together are -(CH<sub>2</sub>)<sub>2</sub>W(CH<sub>2</sub>)<sub>2</sub>-, wherein W is selected from (CH<sub>2</sub>)<sub>n</sub> and n=0-1, -NH, -N(C<sub>1</sub>-C<sub>3</sub>)alkyl, -N-(C<sub>1</sub>-C<sub>4</sub>)alkoxy, oxygen, sulfur or substituted congeners selected from

(L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes.

5. The compound according to Claim 4, wherein

when  $R_1 = \text{hydrogen}$ .

**R<sub>2</sub>** = ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when  $R_1 = \text{methyl}$ .

$R_2$  = methyl, ethyl, n-propyl, n-butyl, 1-methylpropyl, or 2-methylpropyl;

and when  $R_1$  = ethyl,

$R_2$  = ethyl, n-propyl, n-butyl, or 2-methylpropyl;

and when  $R_1$  = n-propyl,

$R_2$  = n-propyl, n-butyl, or 2-methylpropyl;

and when  $R_1$  = n-butyl,

$R_2$  = n-butyl or 2-methylpropyl;

$R_3$  is selected from straight or branched ( $C_1$ - $C_3$ )alkyl group; ( $C_6$ - $C_{10}$ )aryl group; ( $C_7$ - $C_9$ )aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $(CH_2)_nCOOR_5$  when  $n$  = 1-4 and  $R_5$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group; or ( $C_6$ - $C_{10}$ )aryl group;

$R_4$  is selected from straight or branched ( $C_1$ - $C_3$ )alkyl group; ( $C_6$ - $C_{10}$ )aryl group; ( $C_7$ - $C_9$ )aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di( $C_1$ - $C_3$ )alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_6$  when  $n$  = 1-4 and  $R_6$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl; or ( $C_6$ - $C_{10}$ )aryl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n$  = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N( $C_1$ - $C_4$ )-alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes.

$(C_1$ - $C_3$ )alkyl; ( $C_6$ - $C_{10}$ )aryl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n$  = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N( $C_1$ - $C_4$ )-alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes.

6. The compound according to Claim 4, wherein:

when  $R_1$  = hydrogen,

$R_2$  = ethyl, n-propyl or 1-methylethyl;

and when  $R_1$  = methyl,

$R_2$  = methyl, ethyl or n-propyl;

and when  $R_1$  = ethyl,

$R_2$  = ethyl;

$R_3$  is selected from a straight or branched ( $C_1$ - $C_3$ )alkyl group; ( $C_6$ - $C_{10}$ )aryl group; ( $C_7$ - $C_9$ )aralkyl group; or  $-(CH_2)_nCOOR_5$  when  $n$  = 1-4 and  $R_5$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl group; or ( $C_6$ - $C_{10}$ )aryl group;

$R_4$  is selected from straight or branched ( $C_1$ - $C_3$ )alkyl group; ( $C_6$ - $C_{10}$ )aryl group; ( $C_7$ - $C_9$ )aralkyl group; or  $-(CH_2)_nCOOR_6$  when  $n$  = 1-4 and

$R_5$  is selected from hydrogen; straight or branched ( $C_1$ - $C_3$ )alkyl; or ( $C_6$ - $C_{10}$ )aryl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n$  = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N( $C_1$ - $C_4$ )-alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes.

7. The compound according to Claim 1, [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-

tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-

naphthacenecarboxamide p-toluenesulfonate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-methylamino)-

1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-methylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-

28

naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.


5 8. The compound according to Claim 4, [4S-(4 $\alpha$ ,12 $\alpha$ )]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethyl-methylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydro-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide.

10 15 20 25 9. A method of producing a compound of the formula:

25

30

35




35

according to Claim 4, which comprises reacting a 7-(substituted amino)-6-demethyl-6-deoxytetracycline of the formula:

40

45

50




55

with a metal nitrate salt or nitric acid in a strong acid at -5 °C to +5 °C.

10. The process according to Claim 9 wherein said strong acid is selected from sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid.

11. A method of producing a compound of the formula:

5




10

15 according to Claim 1, which comprises reacting a compound of the formula:

20

25



30

according to Claim 4, with a reducing agent.

35

12. The process according to Claim 11, wherein said reducing agent comprises hydrogen in an acidic 2-methoxyethanol solvent, in the presence of a suitable catalyst; stannous chloride; soluble metal sulfide in alcoholic solvents; an active metal in mineral acid; active metal couples; a supported catalyst and a transfer hydrogenation reagent; a primary or secondary amine in the presence of formaldehyde.

13. Use of a compound according to Claim 1 for the preparation of a medicament for the prevention, treatment or control of bacterial infections in warm-blooded animals.

40

14. A pharmaceutical composition of matter comprising a compound according to Claim 1 in association with a pharmaceutically acceptable carrier.

15. A veterinary composition which comprises a pharmacologically effective amount of a compound according to Claim 1 and pharmaceutically acceptable carrier.



45

50

55

**Claims for the following Contracting States : ES, GR**

1. A method of producing a compound of the formula (I) or (II):



25

verein:

when  $R_1$  = hydrogen,  
 $R_2$  = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when  $R_1$  = methyl or ethyl.

$R_2$  = methyl, ethyl, *n*-propyl, 1-methylethyl, *n*-butyl, 1-methylpropyl or 2-methylpropyl;

and when  $R_1 = p$ -propyl

$B_2 \equiv$  *p*-propyl, 1-methylethyl, *p*-butyl, 1-methyl-

$R_2$  = 1-propyl, 1-methylethyl, 1-butyl, 1-methylpropyl or 2-methylpropyl, and when  $B_1$  = 1-methylethyl

35 and when  $R_1 = 1$ -methylpropyl,  
 $R_2 = n$ -butyl, 1-methylpropyl, or

and when  $R_1 = n\text{-butyl}$ ,  $1\text{-methylpropyl}$  or  $2\text{-methylpropyl}$ .

$R_2 = n\text{-butyl, 1-methyl}$

and when  $R_1 = 1\text{-methyl}$


$R_2 = 2\text{-methylpropyl}$ :

40  $R_3$  is selected from

$R_5$  is selected from hydrogen; straight or branched ( $C_1-C_3$ )alkyl,  $(C_6-C_{10})$ aryl,  $(C_6-C_{10})$ alkyl,  $(C_6-C_{10})$ aryl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl,  $\text{di}(C_1-C_3)\text{alkyl}$  substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(\text{CH}_2)_n\text{COOR}_5$  when  $n=1-4$  and  $R_5$  is selected from hydrogen; straight or branched ( $C_1-C_3$ )alkyl group; or ( $C_6-C_{10})$ aryl group;

$C_3$ alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or  $-(CH_2)_nCOOR_6$  when  $n=1-4$  and  $R_6$  is selected from hydrogen; straight or branched ( $C_1-C_3$ )alkyl; or ( $C_6-C_{10}$ )aryl; or  $R_3$  and  $R_4$  taken together are  $-(CH_2)_2W(CH_2)_2-$ , wherein  $W$  is selected from  $(CH_2)_n$  and  $n=0-1$ ,  $-NH$ ,  $-N(C_1-C_3)alkyl$ ,  $-N(C_1-C_4)alkoxy$ , oxygen, sulfur or substituted congeners selected from

50 (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal complexes, which comprises reacting a compound of the formula




wherein R<sub>1</sub> and R<sub>2</sub> are as defined above, with a reducing agent, and, optionally, a selective N-alkylation to obtain a compound of formula (II).

15

2. The process according to Claim 1, wherein said reducing agent comprises hydrogen in an acidic 2-methoxyethanol solvent, in the presence of a suitable catalyst; stannous chloride; soluble metal sulfide in alcoholic solvents; an active metal in mineral acid; active metal couples; a supported catalyst and a transfer hydrogenation reagent; a primary or secondary amine in the presence of formaldehyde.


20

3. A method of producing a compound of the formula



35

wherein R<sub>1</sub> and R<sub>2</sub> are as defined in Claim 1, which comprises reacting a 7-(substituted amino)-6-demethyl-6-deoxytetracycline of the formula



50

with a metal nitrate salt or nitric acid in a strong acid at -5 °C to +5 °C.

4. The process according to Claim 3 wherein said strong acid is selected from sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid.

55

5. The method according to Claim 1 which produces [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12 $\alpha$ -

5 tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide p-toluenesulfonate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-methylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-methylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-methylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide;

10 6. The method according to Claim 3 which produces [4S-(4 $\alpha$ ,12 $\alpha$ )]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide.

40

45



50

55

## Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, PT, SE

5 1. Verbindung der Formel (I) oder (II):



worin:

30 wenn  $R_1 =$  Wasserstoff,  $R_2 =$  Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl oder 1,1-Dimethylethyl;

und, wenn  $R_1 =$  Methyl oder Ethyl,  $R_2 =$  Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl; und, wenn  $R_1 =$  n-Propyl,  $R_2 =$  n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl,

35 und, wenn  $R_1 = 1\text{-Methylethyl}$ ,  $R_2 = n\text{-Butyl}$ ,  $1\text{-Methylpropyl}$  oder  $2\text{-Methylpropyl}$ ;

und, wenn  $R_1 = n\text{-Butyl}$ ,  $R_2 = n\text{-Butyl}$ , 1-Methylpropyl oder 2-Methylpropyl;

und, wenn  $R_1 = 1\text{-Methylpropyl}$ ,  $R_2 = 2\text{-Methylpropyl}$ ;

40 R<sub>3</sub> ist ausgewählt aus Wasserstoff, geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe, C<sub>6</sub>-C<sub>10</sub>-Arylgruppe, C<sub>7</sub>-C<sub>9</sub>-Aralkylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di(C<sub>1</sub>-C<sub>3</sub>)alkyl-substituiertem Pyridyl, Benzofuranyl, Benzothienyl, Chinolinyl oder -(CH<sub>2</sub>)<sub>n</sub>COOR<sub>5</sub>, wenn n = 1-4 und R<sub>5</sub> ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe oder C<sub>6</sub>-C<sub>10</sub>-Arylgruppe;

$R_4$  ist ausgewählt aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe,  $C_6$ - $C_{10}$ -Arylgruppe,  $C_6$ - $C_{10}$ -Arylgruppe, einer heteroaromatischen Gruppe, ausgewählt aus 2-, oder 3-Euryol-, 2-, oder 3-

45 pe, C<sub>7</sub>-C<sub>9</sub>-Arylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di(C<sub>1</sub>-C<sub>3</sub>)alkyl-substituierter Pyridyl, Benzofuranyl, Benzothienyl, Chinolinyl oder -(CH<sub>2</sub>)<sub>n</sub>COOR<sub>6</sub>, wenn n = 1-4 und R<sub>6</sub> ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe oder C<sub>6</sub>-C<sub>10</sub>-Arylgruppe;

oder  $R_3$  und  $R_4$  sind zusammengenommen  $-(CH_2)_2W(CH_2)_2-$ , worin W ausgewählt ist aus  $(CH_2)_n$  und  $n = 0$  oder  $1$ ,  $-NH$ ,  $-N(C_1-C_3)alkyl$ ,  $-N(C_1-C_4)alkoxy$ , Sauerstoff, Schwefel oder substituierte, verwandte Verbindungen, ausgewählt aus (L- oder D-)Prolin, Ethyl(L- oder D-)prolinat, Morphin, Pyrrolidin oder Piperidin und die pharmakologisch akzeptablen organischen oder anorganischen Salze und Metallkomplexe.

## 2. Verbindung nach Anspruch 1, worin:

55 wenn  $R_1 =$  Wasserstoff,  $R_2 =$  Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl oder 1,1-Dimethylethyl; und, wenn  $R_1 =$  Methyl,  $R_2 =$  Methyl, Ethyl, n-Propyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl;

und, wenn  $R_1 = \text{Ethyl}$ ,  $R_2 = \text{Ethyl, n-Propyl, n-Butyl oder 2-Methylpropyl}$ ;

und, wenn  $R_1 = n\text{-Propyl}$ ,  $R_2 = n\text{-Propyl}$ ,  $n\text{-Butyl}$  oder  $2\text{-Methylpropyl}$ ;  
 und, wenn  $R_1 = n\text{-Butyl}$ ,  $R_2 = n\text{-Butyl}$  oder  $2\text{-Methylpropyl}$ ;  
 5  $R_3$  ist ausgewählt aus geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$ ,  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ,  $C_7\text{-}C_9\text{-Aralkylgruppe}$ , einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl,  $\text{Di}(C_1\text{-}C_3)\text{alkyl}\text{-substituiertem Pyridyl}$ , Benzofuranyl, Benzothienyl, Chinolinyl oder  $-(\text{CH}_2)_n\text{COOR}_5$ , wenn  $n = 1\text{-}4$  und  $R_5$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$  oder  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ;  
 10  $R_4$  ist ausgewählt aus geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$ ,  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ,  $C_7\text{-}C_9\text{-Aralkylgruppe}$ , einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl,  $\text{Di}(C_1\text{-}C_3)\text{alkyl}\text{-substituiertem Pyridyl}$ , Benzofuranyl, Benzothienyl, Chinolinyl oder  $-(\text{CH}_2)_n\text{COOR}_6$ , wenn  $n = 1\text{-}4$  und  $R_6$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$  oder  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ;  
 15 oder  $R_3$  und  $R_4$  sind zusammengenommen  $-(\text{CH}_2)_2\text{W}(\text{CH}_2)_2-$ , worin  $W$  ausgewählt ist aus  $(\text{CH}_2)_n$  und  $n = 0$  oder 1,  $-\text{NH}$ ,  $-\text{N}(C_1\text{-}C_3)\text{alkyl}$ ,  $-\text{N}(C_1\text{-}C_4)\text{alkoxy}$ , Wasserstoff, Schwefel oder substituierte, verwandte Verbindungen, ausgewählt aus (L- oder D-)Prolin, Ethyl(L- oder D-)prolinat, Morphin, Pyrrolidin oder Piperidin und die pharmakologisch akzeptablen organischen oder anorganischen Salze und Metallkomplexe.

3. Verbindung nach Anspruch 1, worin:  
 20 wenn  $R_1 = \text{Wasserstoff}$ ,  $R_2 = \text{Ethyl}$ ,  $n\text{-Propyl}$  oder  $1\text{-Methylethyl}$ ; und, wenn  $R_1 = \text{Methyl}$ ,  $R_2 = \text{Methyl}$ ,  $\text{Ethyl}$  oder  $n\text{-Propyl}$ ;  
 und, wenn  $R_1 = \text{Ethyl}$ ,  $R_2 = \text{Ethyl}$ ,  
 25  $R_3$  ist ausgewählt aus geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$ ,  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ,  $C_7\text{-}C_9\text{-Aralkylgruppe}$  oder  $-(\text{CH}_2)_n\text{COOR}_5$ , wenn  $n = 1\text{-}4$  und  $R_5$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$  oder  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ,  $R_4$  ist ausgewählt aus geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$ ,  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ,  $C_7\text{-}C_9\text{-Aralkylgruppe}$  oder  $-(\text{CH}_2)_n\text{COOR}_6$ , wenn  $n = 1\text{-}4$  und  $R_6$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1\text{-}C_3\text{-Alkylgruppe}$  oder  $C_6\text{-}C_{10}\text{-Arylgruppe}$ ,  
 30 oder  $R_3$  und  $R_4$  sind zusammengenommen  $-(\text{CH}_2)_2\text{W}(\text{CH}_2)_2-$ , worin  $W$  ausgewählt ist aus  $(\text{CH}_2)_n$  und  $n = 0$  oder 1,  $-\text{NH}$ ,  $-\text{N}(C_1\text{-}C_3)\text{alkyl}$ ,  $-\text{N}(C_1\text{-}C_4)\text{alkoxy}$ , Wasserstoff, Schwefel oder substituierte, verwandte Verbindungen, ausgewählt aus (L- oder D-)Prolin, Ethyl(L- oder D-)prolinat, Morphin, Pyrrolidin oder Piperidin und die pharmakologisch akzeptablen organischen oder anorganischen Salze und Metallkomplexe.

35



40

45

50

55

## 4. Verbindung der Formel (I) oder (II):



worin:

30 wenn  $R_1$  = Wasserstoff,  $R_2$  = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl oder 1,1-Dimethylethyl; und, wenn  $R_1$  = Methyl oder Ethyl,  $R_2$  = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl; und, wenn  $R_1$  = n-Propyl,  $R_2$  = n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl; und, wenn  $R_1$  = 1-Methylethyl,  $R_2$  = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl; und, wenn  $R_1$  = n-Butyl,  $R_2$  = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl; und, wenn  $R_1$  = 1-Methylpropyl,  $R_2$  = 2-Methylpropyl;  $R_3$  ist ausgewählt aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe,  $C_6$ - $C_{10}$ -Arylgruppe,  $C_7$ - $C_9$ -Aralkylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di( $C_1$ - $C_3$ )alkyl-substituiertem Pyridyl, Benzofuranyl, Benzothienyl, Chinolinyl oder  $-(CH_2)_nCOOR_5$ , wenn  $n$  = 1-4 und  $R_5$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe oder  $C_6$ - $C_{10}$ -Arylgruppe;  $R_4$  ist ausgewählt aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe,  $C_6$ - $C_{10}$ -Arylgruppe,  $C_7$ - $C_9$ -Aralkylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di( $C_1$ - $C_3$ )alkyl-substituiertem Pyridyl, Benzofuranyl, Benzothienyl, Chinolinyl oder  $-(CH_2)_nCOOR_6$ , wenn  $n$  = 1-4 und  $R_6$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe oder  $C_6$ - $C_{10}$ -Arylgruppe; oder  $R_3$  und  $R_4$  sind zusammengenommen  $-(CH_2)_2W(CH_2)_2-$ , worin  $W$  ausgewählt ist aus  $(CH_2)_n$  und  $n$  = 0 oder 1, -NH,  $-N(C_1$ - $C_3)$ alkyl,  $-N(C_1$ - $C_4)$ alkoxy, Sauerstoff oder substituierte, verwandte Verbindungen, ausgewählt aus (L- oder D-)Prolin, Ethyl(L- oder D-)prolinat, Morphin, Pyrrolidin oder Piperidin und die pharmakologisch akzeptablen organischen oder anorganischen Salze und Metallkomplexe.

## 5. Die Verbindung nach Anspruch 4, worin:

wenn  $R_1$  = Wasserstoff,  $R_2$  = Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl oder 1,1-Dimethylethyl; und, wenn  $R_1$  = Methyl,  $R_2$  = Methyl, Ethyl, n-Propyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl; und, wenn  $R_1$  = Ethyl,  $R_2$  = Ethyl, n-Propyl, n-Butyl oder 2-Methylpropyl; und, wenn  $R_1$  = n-Propyl,  $R_2$  = n-Propyl, n-Butyl oder 2-Methylpropyl; und, wenn  $R_1$  = n-Butyl,  $R_2$  = n-Butyl oder 2-Methylpropyl;

R<sub>3</sub> ist ausgewählt aus geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe, C<sub>6</sub>-C<sub>10</sub>-Arylgruppe, C<sub>7</sub>-C<sub>9</sub>-Aralkylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di(C<sub>1</sub>-C<sub>3</sub>)alkyl-substituiertem Pyridyl, Benzofuranyl, Benzothienyl, Chinolinyl oder -(CH<sub>2</sub>)<sub>n</sub>COOR<sub>5</sub>, wenn n = 1-4 und R<sub>5</sub> ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe oder C<sub>6</sub>-C<sub>10</sub>-Arylgruppe;

R<sub>4</sub> ist ausgewählt aus geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe, C<sub>6</sub>-C<sub>10</sub>-Arylgruppe, C<sub>7</sub>-C<sub>9</sub>-Aralkylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di(C<sub>1</sub>-C<sub>3</sub>)alkyl-substituiertem Pyridyl, Benzofuranyl, Benzothienyl, Chinolinyl oder -(CH<sub>2</sub>)<sub>n</sub>COOR<sub>6</sub>, wenn n = 1-4 und R<sub>6</sub> ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe oder C<sub>6</sub>-C<sub>10</sub>-Arylgruppe;

oder R<sub>3</sub> und R<sub>4</sub> sind zusammengenommen -(CH<sub>2</sub>)<sub>2</sub>W(CH<sub>2</sub>)<sub>2</sub>-, worin W ausgewählt ist aus (CH<sub>2</sub>)<sub>n</sub> und n = 0 oder 1, -NH, -N(C<sub>1</sub>-C<sub>3</sub>)alkyl, -N(C<sub>1</sub>-C<sub>4</sub>)alkoxy, Sauerstoff, Schwefel oder substituierte, verwandte Verbindungen, ausgewählt aus (L- oder D-)Prolin, Ethyl(L- oder D-)prolinat, Morphin, Pyrrolidin oder Piperidin und die pharmakologisch akzeptablen organischen oder anorganischen Salze und Metallkomplexe.

6. Verbindung nach Anspruch 4, worin:

wenn R<sub>1</sub> = Wasserstoff, R<sub>2</sub> = Ethyl, n-Propyl oder 1-Methylethyl;  
 und, wenn R<sub>1</sub> = Methyl, R<sub>2</sub> = Methyl, Ethyl oder n-Propyl;  
 und, wenn R<sub>1</sub> = Ethyl, R<sub>2</sub> = Ethyl,

R<sub>3</sub> ist ausgewählt aus geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe, C<sub>6</sub>-C<sub>10</sub>-Arylgruppe, C<sub>7</sub>-C<sub>9</sub>-Aralkylgruppe oder -(CH<sub>2</sub>)<sub>n</sub>COOR<sub>5</sub>, wenn n = 1-4 und R<sub>5</sub> ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe oder C<sub>6</sub>-C<sub>10</sub>-Arylgruppe.

R<sub>4</sub> ist ausgewählt aus geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe, C<sub>6</sub>-C<sub>10</sub>-Arylgruppe, C<sub>7</sub>-C<sub>9</sub>-Aralkylgruppe oder -(CH<sub>2</sub>)<sub>n</sub>COOR<sub>6</sub>, wenn n = 1-4 und R<sub>6</sub> ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter C<sub>1</sub>-C<sub>3</sub>-Alkylgruppe oder C<sub>6</sub>-C<sub>10</sub>-Arylgruppe;

oder R<sub>3</sub> und R<sub>4</sub> sind zusammengenommen -(CH<sub>2</sub>)<sub>2</sub>W(CH<sub>2</sub>)<sub>2</sub>-, worin W ausgewählt ist aus (CH<sub>2</sub>)<sub>n</sub> und n = 0 oder 1, -NH, -N(C<sub>1</sub>-C<sub>3</sub>)alkyl, -N(C<sub>1</sub>-C<sub>4</sub>)alkoxy, Sauerstoff, Schwefel oder substituierte, verwandte Verbindungen, ausgewählt aus (L- oder D-)Prolin, Ethyl(L- oder D-)prolinat, Morphin, Pyrrolidin oder Piperidin und die pharmakologisch akzeptablen organischen oder anorganischen Salze und Metallkomplexe.

7. Verbindung nach Anspruch 1, [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid-Hydrochlorid (1:1); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid-p-Toluolsulfonat (1:1); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:2); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-9-Amino-4-(dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid;

8. Verbindung nach Anspruch 4, [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:2); [4S-(4 $\alpha$ ,12 $\alpha\alpha$ )]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-

Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-4,7-bis(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )]-4-(Dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid.

## 9. Verfahren zum Herstellen einer Verbindung der Formel:

15

20

25

nach Anspruch 4, umfassend das Umsetzen eines 7-(substituierten Amino)-6-Desmethyl-6-desoxytetra-cyclins der Formel:

30

35

40


mit einem Metallnitratsalz oder Salpetersäure in einer starken Säure bei  $-5^{\circ}\text{C}$  bis  $+5^{\circ}\text{C}$ .

45 10. Verfahren nach Anspruch 9, worin die starke Säure ausgewählt ist aus Schwefelsäure, Trifluoressigsäure, Methansulfonsäure oder Perchlorsäure.


50

55

## 11. Verfahren zum Herstellen einer Verbindung der Formel:



nach Anspruch 1, umfassend das Umsetzen einer Verbindung der Formel:



gemäß Anspruch 4. mit einem Reduktionsmittel.

30 12. Verfahren nach Anspruch 11, worin das Reduktionsmittel Wasserstoff in einem sauren 2-Methoxyethanol-Lösungsmittel in Gegenwart eines geeigneten Katalysators, Zinn(II)chlorid, lösliches Metallsulfid in alkoholischen Lösungsmitteln, ein aktives Metall in Mineralsäure, Paarungen bzw. Verbindungen aktiven Metalls, Trägerkatalysator und ein Transfer-Hydrierungsmittel, ein primäres oder sekundäres Amin in Gegenwart von Formaldehyd, umfaßt.

35 13. Verwendung einer Verbindung nach Anspruch 1 zur Herstellung eines Medikaments zur Verhinderung, Behandlung oder Bekämpfung bakterieller Infektionen in warmblütigen Tieren.

40 14. Pharmazeutische Zubereitung, umfassend eine Verbindung nach Anspruch 1 zusammen mit einem pharmazeutisch akzeptablen Träger.

15. Veterinärzubereitung, umfassend eine pharmakologisch wirksame Menge einer Verbindung nach Anspruch 1 und einen pharmazeutisch akzeptablen Träger.

45


50

55

## Patentansprüche für folgende Vertragsstaaten : ES, GR

## 1. Verfahren zum Herstellen einer Verbindung der Formel (I) oder (II):


5



10

15

20



25 worin:

wenn  $R_1$  = Wasserstoff,  $R_2$  = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl oder 1,1-Dimethylethyl;

und, wenn  $R_1$  = Methyl oder Ethyl,  $R_2$  = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl; und, wenn  $R_1$  = n-Propyl,  $R_2$  = n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl,

und, wenn  $R_1$  = 1-Methylethyl,  $R_2$  = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl;

und, wenn  $R_1$  = n-Butyl,  $R_2$  = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl;

und, wenn  $R_1$  = 1-Methylpropyl,  $R_2$  = 2-Methylpropyl;


$R_3$  ist ausgewählt aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe,  $C_6$ - $C_{10}$ -Arylgruppe,  $C_7$ - $C_9$ -Aralkylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di( $C_1$ - $C_3$ )alkyl-substituiertem Pyridyl, Benzofuranyl, Benzothienyl, Chinoliny oder  $-(CH_2)_nCOOR_5$ , wenn  $n$  = 1-4 und  $R_5$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe oder  $C_6$ - $C_{10}$ -Arylgruppe;

$R_4$  ist ausgewählt aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe,  $C_6$ - $C_{10}$ -Arylgruppe,  $C_7$ - $C_9$ -Aralkylgruppe, einer heterocyclischen Gruppe, ausgewählt aus 2- oder 3-Furanyl, 2- oder 3-Thienyl, 2-, 3- oder 4-Pyridyl, Di( $C_1$ - $C_3$ )alkyl-substituiertem Pyridyl, Benzofuranyl, Benzothienyl, Chinoliny oder  $-(CH_2)_nCOOR_6$ , wenn  $n$  = 1-4 und  $R_6$  ausgewählt ist aus Wasserstoff, geradkettiger oder verzweigter  $C_1$ - $C_3$ -Alkylgruppe oder  $C_6$ - $C_{10}$ -Arylgruppe;

oder  $R_3$  und  $R_4$  sind zusammengenommen  $-(CH_2)_2W(CH_2)_2-$ , worin  $W$  ausgewählt ist aus  $(CH_2)_n$  und  $n$  = 0 oder 1, -NH, -N( $C_1$ - $C_3$ )alkyl, -N( $C_1$ - $C_4$ )alkoxy, Sauerstoff oder substituierte, verwandte Verbindungen, ausgewählt aus (L- oder D-)Prolin, Ethyl(L- oder D-)prolinat, Morphin, Pyrrolidin oder Piperidin und die pharmakologisch akzeptablen organischen oder anorganischen Salze und Metallkomplexe, umfassend das Umsetzen einer Verbindung der Formel

50


55



worin  $R_1$  und  $R_2$  die oben genannte Bedeutung haben, mit einem Reduktionsmittel und gegebenenfalls einer selektiven N-alkylierung, um eine Verbindung der Formel (II) zu erhalten.


5 2. Verfahren nach Anspruch 1, worin das Reduktionsmittel Wasserstoff in einem sauren 2-Methoxyethanol-Lösungsmittel in Gegenwart eines geeigneten Katalysators, Zinn(II)chlorid, lösliches Metallsulfid in alkoholischen Lösungsmitteln, ein aktives Metall in Mineralsäure, Paarungen bzw. Verbindungen aktiven Metalls, Trägerkatalysator oder ein Transfer-Hydrierungsmittel, ein primäres oder sekundäres Amin in Gegenwart von Formaldehyd, umfaßt.

### 10 3. Verfahren zum Herstellen einer Verbindung der Formel:



20

woin R<sub>1</sub> und R<sub>2</sub> die in Anspruch 1 angegebene Bedeutung haben, umfassend das Umsetzen eines 7-(substituierten Amino)-6-Desmethyl-6-desoxytetracyclins der Formel:



35

mit einem Metallnitratsalz oder Salpetersäure in einer starken Säure bei -5 °C bis +5 °C.



octahydro-3,10,12,12a-tetrahydroxy-1-11-dioxo-2-naphthacencarboxamid.

6. Verfahren nach Anspruch 3, das erzeugt [4S-(4 $\alpha$ ,12 $\alpha$ )-]4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )-]7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:2); [4S-(4 $\alpha$ ,12 $\alpha$ )-]4-(Dimethylamino)-7-(ethylmethylenamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )-]4-(Dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )-]4-(Dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid-Sulfat (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )-]4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )-]7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )-]4-(Dimethylamino)-7-(ethylmethylenamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )-]4-(Dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid; [4S-(4 $\alpha$ ,12 $\alpha$ )-]4-(Dimethylamino)-7-(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1-11-dioxo-2-naphthacencarboxamid.

## Revendications

## **Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, PT, SE**

25 1. Un composé de formule (I) ou (II) :



dans laquelle :

50 lorsque  $R_1 =$  hydrogène,  
 $R_2 =$  méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle, 2-méthylpropyle ou 1,1-diméthyléthyle ;  
et lorsque  $R_1 =$  méthyle ou éthyle,  
 $R_2 =$  méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

55 et lorsque  $R_1 =$  n-propyle,  
 $R_2 =$  n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;  
et lorsque  $R_1 =$  1-méthyléthyle,  
 $R_2 =$  n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1 = n$ -butyle,  
 $R_2 = n$ -butyle, 1-méthylpropyle ou 2-méthylpropyle ;  
et lorsque  $R_1 = 1$ -méthylpropyle,  
 $R_2 = 2$ -méthylpropyle ;  
5  $R_3$  est choisi parmi l'hydrogène, un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; un groupe hétérocyclique choisi parmi les suivants 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di( $C_1$ - $C_3$ )alkyl substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_5$  lorsque  $n = 1$ -4 et  $R_5$  est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou un groupe ( $C_6$ - $C_{10}$ )aryle ;  
10  $R_4$  est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di( $C_1$ - $C_3$ )alkyl substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_6$  lorsque  $n = 1$ -4 et  $R_6$  est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou un groupe ( $C_6$ - $C_{10}$ )aryle ; ou bien  $R_3$  et  $R_4$  pris ensemble désignent  $-(CH_2)_2W-(CH_2)_2-$ , où  $W$  est choisi parmi ( $CH_2)_n$  et  $n = 0$ -1, -NH, -N( $C_1$ - $C_3$ )alkyle, -N( $C_1$ - $C_4$ )alcoxy, oxygène, soufre ou des congénères substitués choisis parmi la (L ou D) proline, le (L ou D) prolinate d'éthyle, la morpholine, la pyrrolidine ou la pipéridine ; et les sels organiques et inorganiques pharmacologiquement acceptables et les complexes métalliques.

20 2. Le composé selon la revendication 1, selon laquelle :

lorsque  $R_1 =$  hydrogène,  
 $R_2 =$  éthyle,  $n$ -propyle, 1-méthyléthyle,  $n$ -butyle, 1-méthylpropyle, 2-méthylpropyle ou 1,1-diméthyléthyle ;

et lorsque  $R_1 =$  méthyle,

$R_2 =$  méthyle, éthyle,  $n$ -propyle,  $n$ -butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1 =$  éthyle,

$R_2 =$  éthyle,  $n$ -propyle,  $n$ -butyle ou 2-méthylpropyle ;

et lorsque  $R_1 =$   $n$ -propyle,

$R_2 =$   $n$ -propyle,  $n$ -butyle ou 2-méthylpropyle ;

30 et lorsque  $R_1 =$   $n$ -butyle,

$R_2 =$   $n$ -butyle ou 2-méthylpropyle ;

$R_3$  est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di( $C_1$ - $C_3$ )alkyl substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_5$  lorsque  $n = 1$ -4 et  $R_5$  est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou bien un groupe ( $C_6$ - $C_{10}$ )aryle ;

$R_4$  est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di( $C_1$ - $C_3$ )alkyl substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_6$  lorsque  $n = 1$ -4 et  $R_6$  est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou bien  $R_3$  et  $R_4$  pris ensemble désirent  $-(CH_2)_2W-(CH_2)_2-$ , où  $W$  est choisi parmi ( $CH_2)_n$  et  $n = 0$ -1, -NH, -N( $C_1$ - $C_3$ )alkyle, -N( $C_1$ - $C_4$ )alcoxy, oxygène, soufre ou des congénères substitués choisis parmi la (L ou D) proline ou le (L ou D) prolinate d'éthyle, la morpholine, la pyrrolidine ou la pipéridine ; et les sels organiques et inorganiques pharmacologiquement acceptables et les complexes métalliques.

45 3. Le composé selon la revendication 1, selon laquelle :

lorsque  $R_1 =$  l'hydrogène,

$R_2 =$  éthyle,  $n$ -propyle ou 1-méthyléthyle ;

50 et lorsque  $R_1 =$  méthyle,

$R_2 =$  méthyle, éthyle ou  $n$ -propyle ;

et lorsque  $R_1 =$  éthyle,

$R_2 =$  éthyle ;


$R_3$  est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; ou  $-(CH_2)_nCOOR_5$  lorsque  $n = 1$ -4 et  $R_5$  est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou un groupe ( $C_6$ - $C_{10}$ )aryle ;

$R_4$  est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; ou  $-(CH_2)_nCOOR_6$  lorsque  $n = 1$ -4 ;

5  $R_6$  est choisi parmi l'hydrogène ; un groupe  $(C_1-C_3)$ alkyle linéaire ou ramifié ; ou un groupe  $(C_6-C_{10})$ aryle ; ou bien  $R_3$  et  $R_4$  pris ensemble désignent  $-(CH_2)_2W(CH_2)_2-$ , où  $W$  est choisi parmi  $(CH_2)_n$  et  $n = 0-1$ ,  $-NH$ ,  $-N(C_1-C_3)$ alkyle,  $-N(C_1-C_4)$ alcoxy, oxygène, soufre ou des congénères substitués choisis parmi la (L ou D) proline ou le (L ou D) prolinate d'éthyle, la morpholine, la pyrrolidine ou la pipéridine ; et les sels organiques et inorganiques pharmacologiquement acceptables et les complexes métalliques.

4. Un composé de formule (I) ou (II) :

10




15

20

25

30



35

dans laquelle :

lorsque  $R_1$  = hydrogène,

$R_2$  = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle, 2-méthylpropyle ou 1,1-diméthyléthyle ;

et lorsque  $R_1$  = méthyle ou éthyle,

$R_2$  = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = n-propyle,

$R_2$  = n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = 1-méthyléthyle,

$R_2$  = n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = n-butyle,

$R_2$  = n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = 1-méthylpropyle,

$R_2$  = 2-méthylpropyle ;

$R_3$  est choisi parmi l'hydrogène, un groupe  $(C_1-C_3)$ alkyle linéaire ou ramifié ; un groupe  $(C_6-C_{10})$ aryle ;

un groupe  $(C_7-C_9)$ aralkyle ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyl ; 2 ou

50 3-thiényle, 2,3 ou 4-pyridyle, di $(C_1-C_3)$ alkyl substitué pyridyle, benzofuranyl, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_5$  où  $n = 1-4$  et  $R_5$  est choisi parmi l'hydrogène ; un groupe  $(C_1-C_3)$ alkyle linéaire ou ramifié ; ou un groupe  $(C_6-C_{10})$ aryle ;

$R_4$  est choisi parmi l'hydrogène ; un groupe  $(C_1-C_3)$ alkyle linéaire ou ramifié ; un groupe  $(C_6-C_{10})$ aryle ;

un groupe  $(C_7-C_9)$ aralkyle ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyl, 2 ou

55 3-thiényle, 2,3 ou 4-pyridyle, di $(C_1-C_3)$ alkyl substitué pyridyle, benzofuranyl, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_6$  lorsque  $n = 1-4$  et  $R_6$  est choisi parmi l'hydrogène ; un groupe  $(C_1-C_3)$ alkyle linéaire ou ramifié ; ou un groupe  $(C_6-C_{10})$ aryle ; ou bien  $R_3$  et  $R_4$  pris ensemble désirent  $-(CH_2)_2W(CH_2)_2-$ , où  $W$  est choisi parmi  $(CH_2)_n$  et  $n = 0-1$ ,  $-NH$ ,  $-N(C_1-C_3)$ alkyle,  $-N(C_1-C_4)$ alcoxy, oxygène,

soufre ou des congénères substitués choisis parmi la (L ou D) proline, le (L ou D) prolinate d'éthyle, la morpholine, la pyrrolidine ou la pipéridine ; et les sels organiques et inorganiques pharmacologiquement acceptables et les complexes métalliques.

5. Le composé selon la revendication 4, selon laquelle lorsque  $R_1$  = l'hydrogène,  $R_2$  = éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle, 2-méthylpropyle ou 1,1-diméthyléthyle ; et lorsque  $R_1$  = méthyle,  $R_2$  = méthyle, éthyle, n-propyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle ; et lorsque  $R_1$  = éthyle,  $R_2$  = éthyle, n-propyle, n-butyle ou 2-méthylpropyle ; et lorsque  $R_1$  = n-propyle,  $R_2$  = n-propyle, n-butyle ou 2-méthylpropyle ; et lorsque  $R_1$  = n-butyle,  $R_2$  = n-butyle ou 2-méthylpropyle ;  $R_3$  est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di( $C_1$ - $C_3$ )alkyl substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou -( $CH_2$ ) $n$ COOR<sub>5</sub> lorsque  $n$  = 1-4 et R<sub>5</sub> est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou un groupe ( $C_6$ - $C_{10}$ )aryle ; R<sub>4</sub> est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di( $C_1$ - $C_3$ )alkyl substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou -( $CH_2$ ) $n$ COOR<sub>6</sub> lorsque  $n$  = 1-4 et R<sub>6</sub> est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou un groupe ( $C_6$ - $C_{10}$ )aryle ; ou bien R<sub>3</sub> et R<sub>4</sub> pris ensemble désignent -( $CH_2$ )<sub>2</sub>W( $CH_2$ )<sub>2</sub>- , où W est choisi parmi ( $CH_2$ )<sub>n</sub> et n = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyle, -N( $C_1$ - $C_4$ )alcoxy, oxygène, soufre ou des congénères substitués choisis parmi la (L ou D) proline ou le (L ou D) prolinate d'éthyle, la morpholine, la pyrrolidine ou la pipéridine ; et les sels organiques et inorganiques pharmacologiquement acceptables et les complexes métalliques.


6. Le composé selon la revendication 4, selon laquelle lorsque  $R_1$  = hydrogène,  $R_2$  = éthyle, n-propyle ou 1-méthyléthyle ; et lorsque  $R_1$  = méthyle,  $R_2$  = méthyle, éthyle ou n-propyle ; et lorsque  $R_1$  = éthyle,  $R_2$  = éthyle ;  $R_3$  est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; ou -( $CH_2$ ) $n$ COOR<sub>5</sub> lorsque  $n$  = 1-4 et R<sub>5</sub> est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou un groupe ( $C_6$ - $C_{10}$ )aryle ; R<sub>4</sub> est choisi parmi un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; un groupe ( $C_6$ - $C_{10}$ )aryle ; un groupe ( $C_7$ - $C_9$ )aralkyle ; ou -( $CH_2$ ) $n$ COOR<sub>6</sub> lorsque  $n$  = 1-4 et R<sub>6</sub> est choisi parmi l'hydrogène ; un groupe ( $C_1$ - $C_3$ )alkyle linéaire ou ramifié ; ou un groupe ( $C_6$ - $C_{10}$ )aryle ; ou bien R<sub>3</sub> et R<sub>4</sub> pris ensemble désignent -( $CH_2$ )<sub>2</sub>W( $CH_2$ )<sub>2</sub>- , où W est choisi parmi ( $CH_2$ )<sub>n</sub> et n = 0-1, -NH, -N( $C_1$ - $C_3$ )alkyle, -N( $C_1$ - $C_4$ )alcoxy, oxygène, soufre ou des congénères substitués choisis parmi la (L ou D) proline ou le (L ou D) prolinate d'éthyle, la morpholine, la pyrrolidine ou la pipéridine ; et les sels organiques et inorganiques pharmacologiquement acceptables et les complexes métalliques.

7. Le composé selon la revendication 1, à savoir le suivant : [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4,7-bis(diméthyléthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide, sulfate (1:1); [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4,7-bis(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide, chlorhydrate (1:1) ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4,7-bis(diméthylamino)-1,4,4a,5,5a,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide, p-toluenesulfonate (1:1) ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-7-(diéthylamino)-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide, sulfate (1:2) ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4-(diméthylamino)-7-(éthyl-méthylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4-(diméthylamino)-7-[(1-méthyléthyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-


3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4-(diméthylamino)-7-(éthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4,7-bis(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-7-(diéthylamino)-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4-(diméthylamino)-7-(éthylméthylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4-(diméthylamino)-7-[(1-méthyléthyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4-(diméthylamino)-7-(éthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphtacène carboxamide.

8. Le composé selon la revendication 4 qui est le suivant : [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4,7-bis(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-7-(diéthylamino)-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide, sulfate (1:2) ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4-(diméthylamino)-7-(éthylméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydro-9-nitro-1,11-dioxo-2-naphtacènecarboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4-(diméthylamino)-7-[(1-méthyléthyl)-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4-(diméthylamino)-7-(éthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4,7-bis(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-7-(diéthylamino)-4-(diméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4-(diméthylamino)-7-(éthylméthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydro-9-nitro-1,11-dioxo-2-naphtacènecarboxamide ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4-(diméthylamino)-7-[(1-méthyléthyl)-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4-(diméthylamino)-7-(éthylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide ; [4S-(4 $\alpha$ , 12 $\alpha$ )-]-4-(diméthylamino)-7-[(1-méthyléthyl)-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-9-nitro-1,11-dioxo-2-naphtacènecarboxamide.

9. Une méthode de production d'un composé de formule :




45 selon la revendication 4, qui comprend la réaction d'un 7-(amino substitué)-6-déméthyl-6-désoxytétracycline de formule :




avec un sel nitrate métallique ou l'acide nitrique dans un acide fort à -5 °C à +5 °C.

10. Le procédé selon la revendication 9, selon laquelle ledit acide fort est choisi parmi l'acide sulfurique, l'acide trifluoroacétique, l'acide méthanesulfonique ou l'acide perchlorique.

## 11. Une méthode de production d'un composé de formule :



selon la revendication 1, qui comprend la réaction d'un composé de formule :



selon la revendication 4 avec un agent réducteur.

12. Le procédé selon la revendication 11, selon laquelle ledit agent réducteur comprend l'hydrogène dans un solvant 2-méthoxyéthanol acide, en présence d'un catalyseur approprié ; de chlorure stanneux ; de sulfure métallique soluble dans des solvants alcooliques ; d'un métal actif dans un acide minéral ; des couples de métaux actifs ; d'un catalyseur sur support et d'un réactif d'hydrogénéation par transfert ; d'une amine primaire ou secondaire en présence de formaldéhyde.

13. Utilisation d'un composé selon la revendication 1, pour la préparation d'un médicament pour la prévention, le traitement ou le contrôle des infections bactériennes chez les animaux à sang chaud.

14. Une composition pharmaceutique comprenant un composé selon la revendication 1 en association avec un support pharmaceutiquement acceptable.


15. Une composition vétérinaire qui comprend une quantité pharmacologique efficace d'un composé selon la revendication 1 et un support pharmaceutiquement acceptable.

**Revendications pour les Etats contractants suivants : ES, GR**

5

1. Une méthode de production d'un composé de formule (I) ou (II) :


10



15

20

25



30

dans laquelle :

lorsque  $R_1$  = hydrogène,

$R_2$  = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle, 2-méthylpropyle ou 1,1-diméthyléthyle ;

35

et lorsque  $R_1$  = méthyle ou éthyle,

$R_2$  = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = n-propyle,

$R_2$  = n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = 1-méthyléthyle,

40

$R_2$  = n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = n-butyle,

$R_2$  = n-butyle, 1-méthylpropyle ou 2-méthylpropyle ;

et lorsque  $R_1$  = 1-méthylpropyle,


$R_2$  = 2-méthylpropyle ;

45

$R_3$  est choisi parmi l'hydrogène, un groupe  $(C_1-C_3)alkyle$  linéaire ou ramifié ; un groupe  $(C_6-C_{10})aryle$  ; un groupe  $(C_7-C_9)aralkyle$  ; un groupe hétérocyclique choisi parmi les suivants 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di $(C_1-C_3)alkyl$  substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_5$  lorsque  $n = 1-4$  et  $R_5$  est choisi parmi l'hydrogène ; un groupe  $(C_1-C_3)alkyle$  linéaire ou ramifié ; ou un groupe  $(C_6-C_{10})aryle$  ;

50


$R_4$  est choisi parmi l'hydrogène ; un groupe  $(C_1-C_3)alkyle$  linéaire ou ramifié ; un groupe  $(C_6-C_{10})aryle$  ; un groupe  $(C_7-C_9)aralkyle$  ; un groupe hétérocyclique choisi parmi les suivants : 2 ou 3-furanyle, 2 ou 3-thiényle, 2,3 ou 4-pyridyle, di $(C_1-C_3)alkyl$  substitué pyridyle, benzofuranyle, benzothiényle, quinolinyle ou  $-(CH_2)_nCOOR_6$  lorsque  $n = 1-4$  et  $R_6$  est choisi parmi l'hydrogène ; un groupe  $(C_1-C_3)alkyle$  linéaire ou ramifié ; ou un groupe  $(C_6-C_{10})aryle$  ; ou bien  $R_3$  et  $R_4$  pris ensemble désignent  $-(CH_2)_2W-(CH_2)_2-$ , où  $W$  est choisi parmi  $(CH_2)_n$  et  $n = 0-1$ ,  $-NH$ ,  $-N(C_1-C_3)alkyle$ ,  $-N(C_1-C_4)alcoxy$ , oxygène, soufre ou des congénères substitués choisis parmi la (L ou D) proline, le (L ou D) prolinate d'éthyle, la morpholine, la pyrrolidine ou la pipéridine ; et les sels organiques et inorganiques pharmacologiquement acceptables et les complexes métalliques qui comprend la réaction de composé de formule :




dans laquelle R<sub>1</sub> et R<sub>2</sub> sont comme définis précédemment, avec un agent réducteur et, éventuellement, une N-alkylation sélective pour obtenir un composé de formule (II).

15 2. Le procédé selon la revendication 1, selon laquelle ledit agent réducteur comprend de l'hydrogène dans un solvant 2-méthoxyéthanol acide, en présence d'un catalyseur approprié ; le chlorure stanneux ; un sulfure métallique soluble dans les solvants alcooliques ; un métal actif dans un acide minéral ; des couples de métaux actifs ; un catalyseur sur support et un réactif d'hydrogénéation par transfert ; une  
20 amine primaire ou secondaire en présence de formaldéhyde.

3. Une méthode de production d'un composé de formule :



35 dans laquelle R<sub>1</sub> et R<sub>2</sub> sont comme définis dans la revendication 1, qui comprend la réaction d'une 7-(  
(amino substitué)-6-déméthyl-6-désoxytétracycline de formule



50 avec un sel nitrate métallique ou avec l'acide nitrique dans un acide fort à -5 °C à +5 °C.

4. Le procédé selon la revendication 3, selon laquelle l'édit acide fort est choisi parmi l'acide sulfurique, l'acide trifluoroacétique, l'acide méthanesulfonique et l'acide perchlorique.

55

5. La méthode selon la revendication 1 qui produit les composés suivants : [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino)-4,7-bis(diméthyléthylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tétrahydroxy-1,11-dioxo-2-naphthacènecarboxamide, sulfate (1:1) ; [4S-(4 $\alpha$ ,12 $\alpha$ )]-9-amino-4,7-bis(diméthylamino)-1,4,4a,5,5a,6,11,12a-oc-

40

45

50